New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | all day >>
08:27 EDTTYCTyco sees FY15 EPS ex-restructuring $2.40, consensus $2.40
Subscribe for More Information
08:25 EDTMACKMerrimack presents data from Phase 1 studies of MM-398, MM-151
Merrimack Pharmaceuticals announced data from multiple presentations. Data presented includes the first public presentation on the preclinical activity and potency of MM-131, and preclinical and clinical data on MM-151. An additional abstract details Phase 1 results from a clinical pilot study evaluating the feasibility of using ferumoxytol, an iron oxide nanoparticle, as a proxy to determine tumor responses to MM-398, nanoliposomal irinotecan. Computational modeling predicted that MM-131 would block HGF from binding to c-Met with higher potency through concurrent binding to epithelial cell adhesion molecule, an abundant protein on the cell surface of many cancer types. The models also suggested that the potency of MM-131 would increase with higher levels of EpCAM, as binding to EpCAM enables MM-131 to concentrate at the cell surface and effectively compete with HGF binding to c-Met. Preclinical studies validated this prediction and MM-131 was shown to inhibit HGF-mediated pathway activation and both the growth and migration of tumor cells across a panel of cell lines in vitro. Additionally, MM-131 inhibits tumor growth in models of c-Met-driven cancer in vivo. Overall, ferumoxytol was well tolerated. Adverse events of MM-398 therapy were consistent with previous studies, and no adverse events were directly attributable to ferumoxytol.
08:23 EDTHRLHormel Foods December volatility increases into Q4 and outlook
Subscribe for More Information
08:23 EDTEBAYeBay downgraded to Sell from Hold at Evercore ISI
Subscribe for More Information
08:22 EDTVLKAYVolkswagen to invest EUR 85.6B in new models, technologies over five years
The Volkswagen Group will invest a total of EUR 85.6B in new models, innovative technologies and its global presence in its Automotive Division over the coming five years. Around two-thirds of the total investment amount will flow into increasingly efficient vehicles, drives and more environmentally friendly production. This is the result of the Group’s investment planning for 2015 to 2019 discussed by the Supervisory Board of Volkswagen Aktiengesellschaft at its meeting. “We will continue to invest in the future to become the leading automotive group in both ecological and economic terms – with the best and most sustainable products”, said Prof. Dr. Martin Winterkorn, Chairman of the Board of Management of Volkswagen Aktiengesellschaft, in Wolfsburg. “Development costs will remain high in the future as a result of high innovation pressure and increasing demands on the automotive industry from CO2 legislation. As a Group, we have the expertise and financial strength to continue to extend our technology leadership and to reach our goals for 2018.” Investments in property, plant and equipment, investment property and intangible assets, excluding capitalized development costs in the Automotive Division will amount to EUR 64.3B across the planning horizon as a whole, on a level with the planning approved in the previous year for the period from 2014 to 2018. In addition to spending on capex, the plans also include capitalized development costs of EUR 21.9 billion and proceeds from asset disposals of EUR 0.6B, net of investments in financial assets. The Group will spend most of the total capex in the Automotive Division on modernizing and extending the product range for all its brands.
08:22 EDTSPLKSplunk price target raised to $78 from $68 at JMP Securities
Subscribe for More Information
08:20 EDTBOXBox CEO says IPO still on file, acknowledges 'should not have filed when we did'
Subscribe for More Information
08:19 EDTPANWPalo Alto results, guidance should beat expectations, says JMP Securities
JMP Securities expects Palo Alto's Q1 results and its guidance to beat consensus estimates. The firm thinks the company benefited from strong demand for next generation security technologies as well as share gains from legacy firewall vendors.
08:18 EDTMDVNMedivation management to meet with Deutsche Bank
Subscribe for More Information
08:18 EDTARUNAruba Networks outlook still positive, says JMP Securities
Subscribe for More Information
08:17 EDTOMEDOncoMed presents data from tarextumab, demcizumab trials
OncoMed Pharmaceuticals presented data in two posters highlighting the company's translational research and biomarker efforts for its tarextumab and demcizumab clinical programs Jakob Dupont, M.D., OncoMed's Chief Medical Officer, stated, "The data from the Phase 1b clinical trials of tarextumab and demcizumab demonstrate that our preclinical understanding of on-target drug activity and predictive biomarkers is being validated in the clinic as we study actual patient tumor samples. In the ALPINE Phase 1b study in advanced pancreatic cancer, we see clear evidence that tarextumab modulates the Notch cancer stem cell pathway in patient samples and that there is a potential association between tumors that show higher levels of Notch3 gene expression and best responses to tarextumab treatment. In the demcizumab poster presentation, a case study is described from our Phase 1b trial in pancreatic cancer in which the tumor response to treatment that occurred in the clinic correlates with what we observe using patient-derived xenograft models. This may provide insights into the development of potential biomarkers of response to demcizumab treatment in that program."
08:17 EDTDHID.R. Horton upgraded to Market Perform from Underperform at Raymond James
Subscribe for More Information
08:17 EDTKBHKB Home upgraded to Market Perform from Underperform at Raymond James
Subscribe for More Information
08:17 EDTMDCM.D.C. Holdings upgraded to Market Perform from Underperform at Raymond James
Raymond James upgraded M.D.C. Holdings to Market Perform based on historical seasonal sector strength. The firm still has concerns regarding relative valuations and land quality.
08:17 EDTSPFStandard Pacific downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information
08:15 EDTNUVANuVasive price target raised to $48 from $44 at Summer Street
Subscribe for More Information
08:15 EDTTLM, ECTalisman Energy, Ecopetrol announce discovery in Block CPO-9, Colombia
Talisman Energy (TLM) affiliate Talisman Oil & Gas and Ecopetrol S.A. (ECP) have proven the presence of hydrocarbons in the Nueva Esperanza-1 exploratory well, located in block CPO-9, Department of Meta, Colombia. The Nueva Esperanza-1 well was spudded on July 18, 2014 and reached total depth at 12,056 feet on September 26, 2014. During an initial 8-day flow test using an electro submersible pumping system, 309 feet of perforations in the T2 formation stabilized at a daily flow rate of 910 barrels of 8 degrees API crude oil with less than 2% water cut during the last day of flow. Talisman and Ecopetrol are jointly analyzing the results and will file an application with the Colombian authorities to place the Nueva Esperanza-1 well on long-term test. Approval has been granted to drill two down-dip appraisal wells, the first of which, Nueva Esperanza-2, started drilling operations on November 16.
08:14 EDTHMC, TM, MZDAF, BAMXY, NSANY, FCAU, F, GMHonda warned Takata on airbags years before recalls, WSJ reports
Subscribe for More Information
08:11 EDTFISVFiserv initiated with a Hold at Topeka
Subscribe for More Information
08:11 EDTROSTRoss Stores upgraded to Hold from Sell at Maxim
Maxim upgraded Ross Stores to Hold following the Q3 report and guidance citing a sales acceleration.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use